JP2022545156A5 - - Google Patents

Info

Publication number
JP2022545156A5
JP2022545156A5 JP2022502090A JP2022502090A JP2022545156A5 JP 2022545156 A5 JP2022545156 A5 JP 2022545156A5 JP 2022502090 A JP2022502090 A JP 2022502090A JP 2022502090 A JP2022502090 A JP 2022502090A JP 2022545156 A5 JP2022545156 A5 JP 2022545156A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
solid pharmaceutical
composition according
dapagliflozin
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022502090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/072106 external-priority patent/WO2021023811A1/en
Publication of JP2022545156A publication Critical patent/JP2022545156A/ja
Publication of JP2022545156A5 publication Critical patent/JP2022545156A5/ja
Withdrawn legal-status Critical Current

Links

JP2022502090A 2019-08-07 2020-08-06 Glp-1作動薬と、sglt2阻害剤と、n-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物 Withdrawn JP2022545156A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19190623.9 2019-08-07
EP19190623 2019-08-07
EP20172415 2020-04-30
EP20172415.0 2020-04-30
PCT/EP2020/072106 WO2021023811A1 (en) 2019-08-07 2020-08-06 Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (2)

Publication Number Publication Date
JP2022545156A JP2022545156A (ja) 2022-10-26
JP2022545156A5 true JP2022545156A5 (https=) 2023-07-13

Family

ID=71894842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502090A Withdrawn JP2022545156A (ja) 2019-08-07 2020-08-06 Glp-1作動薬と、sglt2阻害剤と、n-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物

Country Status (16)

Country Link
US (1) US20220265777A1 (https=)
EP (1) EP4009941A1 (https=)
JP (1) JP2022545156A (https=)
KR (1) KR20220044269A (https=)
CN (1) CN114173766A (https=)
AU (1) AU2020325708A1 (https=)
BR (1) BR112022000490A2 (https=)
CA (1) CA3144611A1 (https=)
CL (1) CL2022000137A1 (https=)
CO (1) CO2022000578A2 (https=)
IL (1) IL289504A (https=)
MX (1) MX2022000827A (https=)
PE (1) PE20220751A1 (https=)
PH (1) PH12022550007A1 (https=)
TW (1) TW202114730A (https=)
WO (1) WO2021023811A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI797133B (zh) * 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
JP6898518B2 (ja) * 2018-02-02 2021-07-07 ノヴォ ノルディスク アー/エス Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物
WO2022268214A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 Pcsk9抑制剂和glp-1受体激动剂的药物组合
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
CN114085203A (zh) * 2021-12-17 2022-02-25 宁波高新区美诺华医药创新研究院有限公司 达格列净组合物
CN118742326A (zh) * 2021-12-29 2024-10-01 广州大洲生物医药科技有限公司 口服递送
CN116370609B (zh) * 2023-06-01 2023-08-15 北京普诺旺康医药科技有限公司 包含血管活性肠肽和吸收增强剂的固体组合物
KR20250103515A (ko) * 2023-12-28 2025-07-07 주식회사 대웅제약 이나보글리플로진와 저용량 리라글루타이드의 항비만 병용 요법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105503802A (zh) * 2016-01-15 2016-04-20 中山大学 一种达格列净-柠檬酸共晶的制备方法
WO2018124497A1 (ko) * 2016-12-30 2018-07-05 한미약품 주식회사 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
TWI797133B (zh) * 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物

Similar Documents

Publication Publication Date Title
JP2022545156A5 (https=)
JP2023002662A5 (https=)
JP4077320B2 (ja) 5−メチル−1−フェニル−2−(1h)−ピリドンを有効成分として含有する医薬製剤
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
JP2021523149A5 (https=)
HRP20231613T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
JP2015512406A5 (https=)
JP2015510916A5 (https=)
JP2021504384A5 (https=)
JP2019533660A5 (https=)
JP2023500032A5 (https=)
JP2008533127A5 (https=)
JP7523879B2 (ja) 医薬組成物
ES2197087T3 (es) Tabletas tragables con alto contenido de n-acetilcisteina.
JP5403935B2 (ja) 経口用の慢性疼痛予防または治療剤
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
US9561204B2 (en) Effervescent compositions containing N-acetylcysteine
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP7123205B2 (ja) 経口用医薬組成物
JP2026509388A (ja) 経口投与用のglp作動薬の医薬組成物
EP2959891A1 (en) Modified release pharmaceutical compositions of sofosbuvir and ribavirin
JP5134802B2 (ja) 塩酸ブロムヘキシン含有量低下の防止方法
JP7355846B2 (ja) 固形製剤
JP6280303B2 (ja) 感冒薬組成物
ES2952013T3 (es) Combinación de ibuprofeno y tramadol para aliviar el dolor